Literature DB >> 3050937

The diagnosis and classification of scleroderma (systemic sclerosis).

A J Barnett1, M Miller, G O Littlejohn.   

Abstract

Difficulty in the diagnosis of the disease scleroderma may occur at the early stage prior to the development of obvious skin sclerosis. A presumptive diagnosis may be made if Raynaud's phenomenon is accompanied by a positive 'neck test', 'scleroderma' capillary changes in the nailfolds or antinuclear antibodies. Definitive diagnosis may have to be delayed for several years from the onset of Raynaud's phenomenon until definite characteristic skin changes are seen. Ten cases in which an earlier diagnosis of scleroderma was not substantiated are listed. The earlier incorrect diagnosis would have been avoided by use of the methods described in this paper. Various terms have been used to denote subdivisions of scleroderma. These include acrosclerosis, diffuse scleroderma and CREST. We have used the terms Type 1, Type 2 and Type 3 based on the early extent of the skin sclerosis where Type 1 (limited extent) indicates sclerodactyly only, Type 2 (moderate extent) indicates sclerosis proximal to the metacarpophalangeal joints but excluding the trunk and Type 3 (extensive) indicates diffuse skin sclerosis including the trunk. The clinical value of this simple classification is reviewed and contrasted to other classifications which appear to be poorly defined and of limited use.

Entities:  

Mesh:

Year:  1988        PMID: 3050937      PMCID: PMC2428791          DOI: 10.1136/pgmj.64.748.121

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  19 in total

1.  MULTIPLE TELANGIECTASIA, RAYNAUD'S PHENOMENON, SCLERODACTYLY, AND SUBCUTANIOUS CALCINOSIS: A SYNDROME MIMICKING HEREDITARY HEMORRHAGIC TELANGIECTASIA.

Authors:  R H WINTERBAUER
Journal:  Bull Johns Hopkins Hosp       Date:  1964-06

2.  Diffuse systemic scleroderma. A comparison with acrosclerosis.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Ann Intern Med       Date:  1962-08       Impact factor: 25.391

3.  Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases.

Authors:  R G FARMER; R W GIFFORD; E A HINES
Journal:  Circulation       Date:  1960-06       Impact factor: 29.690

4.  Acrosclerosis: a disease sui generis or a variety of diffuse scleroderma.

Authors:  S JABLONSKA; B BUBNOW; B LUKASIAK
Journal:  Br J Dermatol       Date:  1959-04       Impact factor: 9.302

5.  Scleroderma; based on a study of over 150 cases.

Authors:  I LEINWAND; A W DURYEE; M N RICHTER
Journal:  Ann Intern Med       Date:  1954-11       Impact factor: 25.391

6.  Progressive systemic sclerosis sine scleroderma.

Authors:  G P RODNAN; R H FENNELL
Journal:  JAMA       Date:  1962-05-26       Impact factor: 56.272

7.  Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; N Talal; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

8.  Scleroderma. 1. Clinical features, course of illness and response to treatment in 61 cases.

Authors:  A J Barnett; D A Coventry
Journal:  Med J Aust       Date:  1969-05-10       Impact factor: 7.738

9.  The systemic involvement in scleroderma.

Authors:  A J Barnett
Journal:  Med J Aust       Date:  1977-11-12       Impact factor: 7.738

10.  Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases.

Authors:  G C Sharp; W S Irvin; C M May; H R Holman; F C McDuffie; E V Hess; F R Schmid
Journal:  N Engl J Med       Date:  1976-11-18       Impact factor: 91.245

View more
  8 in total

1.  Vascular leak is a central feature in the pathogenesis of systemic sclerosis.

Authors:  Tracy M Frech; Monica P Revelo; Stavros G Drakos; Maureen A Murtaugh; Boaz A Markewitz; Allen D Sawitzke; Dean Y Li
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

Review 2.  Diagnosis and classification of systemic sclerosis.

Authors:  Eric Hachulla; David Launay
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 3.  Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling.

Authors:  Jennifer L Sargent; Michael L Whitfield
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

Review 4.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008

5.  A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Authors:  Jennifer L Sargent; Ausra Milano; Swati Bhattacharyya; John Varga; M Kari Connolly; Howard Y Chang; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

6.  Are There Clinical Differences in Limited Systemic Sclerosis according to Extension of Skin Involvement?

Authors:  Marina Scolnik; Luis J Catoggio; Eliana Lancioni; Mirtha R Sabelli; Carla M Saucedo; Josefina Marin; Enrique R Soriano
Journal:  Int J Rheumatol       Date:  2014-11-11

Review 7.  Enigmatic insight into collagen.

Authors:  Shrutal Narendra Deshmukh; Alka M Dive; Rohit Moharil; Prashant Munde
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug

Review 8.  Extrahepatic Manifestations of Primary Biliary Cholangitis.

Authors:  Sara L Chalifoux; Peter G Konyn; Gina Choi; Sammy Saab
Journal:  Gut Liver       Date:  2017-11-15       Impact factor: 4.519

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.